HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.
Clene FY EPS $(0.46) Beats $(0.58) Estimate, Sales $473.00K Beat $340.00K Estimate; Cash, Cash Equivalents & Marketable Securities Of $23.3M Sufficient To Fund Its Operations Into Q3 Of 2023
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 187.5 percent decrease over losses of $(0.16) per share from the same
Cantor Fitzgerald Maintains Buy on Clene, Raises Price Target to $8
Cantor Fitzgerald analyst Charles Duncan maintains Clene (NASDAQ:CLNN) with a Buy and raises the price target from $6 to $8.
Clene’s Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows
Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…
Clene’s Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression
Clene Inc (NASDAQ:CLNN) announced new results showing preserved ALS patient functional score (ALSFRS-R) and delayed time to clinical worsening from the…
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 146.5% to $1.14 during Monday’s regular session. As of 12:30…
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.
Clene Shares Move Higher On Encouraging Data From Multiple Sclerosis Candidate
Clene Inc (NASDAQ:CLNN) announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple…